Literature DB >> 24158023

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

U Chakravarthy1, M Williams1.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 24158023      PMCID: PMC3869519          DOI: 10.1038/eye.2013.233

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  25 in total

1.  Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3.

Authors: 
Journal:  Ophthalmology       Date:  2000-12       Impact factor: 12.079

Review 2.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.

Authors:  Tien Y Wong; Tien Wong; Usha Chakravarthy; Ronald Klein; Paul Mitchell; Gergana Zlateva; Ronald Buggage; Kyle Fahrbach; Corey Probst; Isabella Sledge
Journal:  Ophthalmology       Date:  2007-08-06       Impact factor: 12.079

3.  Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study.

Authors:  Ronald Klein; Barbara E K Klein; Michael D Knudtson; Stacy M Meuer; Maria Swift; Ronald E Gangnon
Journal:  Ophthalmology       Date:  2007-02       Impact factor: 12.079

Review 4.  Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis.

Authors:  Elaine W-T Chong; Tien Y Wong; Andreas J Kreis; Julie A Simpson; Robyn H Guymer
Journal:  BMJ       Date:  2007-10-08

5.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

7.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-10

8.  Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration.

Authors:  J S Sunness; J Gonzalez-Baron; C A Applegate; N M Bressler; Y Tian; B Hawkins; Y Barron; A Bergman
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

Review 9.  How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?

Authors:  C G Owen; A E Fletcher; M Donoghue; A R Rudnicka
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

10.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves
Journal:  Lancet       Date:  2013-07-19       Impact factor: 79.321

View more
  18 in total

1.  The effects of ocular magnification on Spectralis spectral domain optical coherence tomography scan length.

Authors:  Irene Ctori; Stephen Gruppetta; Byki Huntjens
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-10       Impact factor: 3.117

Review 2.  Defining response to anti-VEGF therapies in neovascular AMD.

Authors:  W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang
Journal:  Eye (Lond)       Date:  2015-04-17       Impact factor: 3.775

3.  [Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)].

Authors:  F Ziemssen; T Bertelmann; U Hufenbach; M Scheffler; S Liakopoulos; S Schmitz-Valckenberg
Journal:  Ophthalmologe       Date:  2016-02       Impact factor: 1.059

4.  A Comparative Study of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes of Polish Therapeutic Program in Non-Tertiary Institution.

Authors:  Tomasz Skrzypczak; Aleksandra Jany; Ewa Bugajska-Abramek; Joanna Bogusławska; Agnieszka Kowal-Lange
Journal:  Cureus       Date:  2021-06-25

5.  Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration.

Authors:  Tiarnan D L Keenan; Usha Chakravarthy; Anat Loewenstein; Emily Y Chew; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2021-02-15       Impact factor: 5.258

6.  Repeatability of Foveal Measurements Using Spectralis Optical Coherence Tomography Segmentation Software.

Authors:  Irene Ctori; Byki Huntjens
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

7.  The concordance of care for age related macular degeneration with the chronic care model: a multi-centered cross-sectional study.

Authors:  Stefan Markun; Elisabeth Brändle; Avraham Dishy; Thomas Rosemann; Anja Frei
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

8.  Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment.

Authors:  Norihiro Nagai; Misa Suzuki; Atsuro Uchida; Toshihide Kurihara; Mamoru Kamoshita; Sakiko Minami; Hajime Shinoda; Kazuo Tsubota; Yoko Ozawa
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

9.  Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study.

Authors:  Peng Yong Sim; Sonul Gajree; Baljean Dhillon; Shyamanga Borooah
Journal:  BMJ Open       Date:  2017-12-10       Impact factor: 2.692

10.  Age-related macular degeneration.

Authors:  Wanjiku Mathenge
Journal:  Community Eye Health       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.